{"id":66729,"date":"2025-04-16T12:01:41","date_gmt":"2025-04-16T12:01:41","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2025\/04\/16\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/"},"modified":"2025-04-16T12:01:41","modified_gmt":"2025-04-16T12:01:41","slug":"oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/","title":{"rendered":"OncoC4 Selected to Present at the 2025 AACR Meeting&#8217;s Showcase Session"},"content":{"rendered":"<div>\n<p align=\"center\"><em>Oral presentation will feature AI-081, a potentially best-in-class PD-1\/VEGF bispecific antibody and ONC-841, a first-in-class anti-Siglec-10 antibody<\/em><\/p>\n<p align=\"center\"><em>Initial clinical data for both AI-081 and ONC-841 in solid tumors expected 2H 2025<\/em><\/p>\n<p align=\"justify\">ROCKVILLE, Md., April  16, 2025  (GLOBE NEWSWIRE) &#8212; OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer today announced that it will present during the Showcase Session at the 2025 American Association for Cancer Research (AACR) Oncology Industry Partnering Event being held April 24-25, 2025, in Chicago, Illinois. The Showcase Session is a new addition to the 2025 program that features companies selected from a competitive application process.<\/p>\n<p align=\"justify\">\u201cWe are pleased to be selected to share recent progress across our pipeline of best-in-class and first-in-class drugs targeting both validated and novel immune checkpoints at this year\u2019s AACR Showcase Session,\u201d said Yang Liu, PhD, Co-Founder, Chief Executive Officer and Chief Scientific Officer of OncoC4.\u00a0\u201cOur two lead wholly owned programs are advancing in the clinic including AI-081, a differentiated PD-1\/VEGF bispecific antibody with stronger cooperative interactions and the potential for superior patient outcomes, and ONC-841, an anti-Siglec-10 antibody that promotes anti-tumor immunity by blocking the novel immune checkpoint implicated in tumor evasion. Both candidates have the potential to significantly impact the treatment landscape for solid tumors, and we look forward to initial dose-escalation data for both programs in advanced solid tumors in the second half of 2025.\u201d<\/p>\n<p align=\"justify\"><strong>Showcase Session Corporate Presentation Details<\/strong><br \/>Date: Thursday, April 24, 2025<br \/>Time: 5:05 p.m. ET<br \/>Session: Showcase Session 2 (W192)<br \/>Presenter: Pan Pan, Senior Vice President of Business Development<\/p>\n<p><strong>About OncoC4<\/strong><\/p>\n<p>Based in Rockville, Maryland, OncoC4 is a privately held, late-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for the treatment of cancer and immunological diseases. OncoC4 has a pipeline of first-in-class and best-in-class assets targeting both novel and well validated targets in oncology and immunological diseases. Among them, AI-081 is a fully owned and potentially best-in-class bispecific antibody targeting PD-1 and VEGF. AI-081 is currently enrolling patients in a Phase 1\/2 trial that could enable two or more pivotal studies. Its lead clinical candidate is gotistobart (BNT316\/ONC-392), a next generation anti-CTLA-4 antibody that allows CTLA-4 to recycle and maintain its protective function against autoimmune diseases while enhancing anti-tumor activity at the same time.\u00a0In March 2023, OncoC4 announced a strategic collaboration with BioNTech to co-develop and commercialize ONC-392 in multiple solid tumor indications. OncoC4 received $200M upfront and is eligible to receive development, regulatory, and commercial milestone payments in addition to double digit royalties.<\/p>\n<p>More information:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=irOjETCZ0-a48yXmRhHs7Eua_k9ZvieZnm_ukQKTT6dE8c40YMSRISMeL3YQQ13k700dMCe0uOBEj-vgHmXNlg==\" rel=\"nofollow\" target=\"_blank\" title=\"www.oncoc4.com\">www.oncoc4.com<\/a>.<\/p>\n<p><strong>CONTACTS<\/strong><\/p>\n<p><strong>OncoC4<\/strong><br \/><strong>Investor Contact:<\/strong><\/p>\n<p>Bill Begien<br \/>OncoC4, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fmkT5n4R1pGF45cmNcefhkeXaOoOyguVloXt2anF6rtbOp_XKo0MtpcxaNmrJXMYxy85-gqvx8OmuG8AETEHGVBX330g2vNVASVD2OakTwh9InIsSYnb_JEVqQIFO1LHfpdK0YYZDjlADBQojk4Wkgck39-w950MEhUtLAG9qTxFxC0GPeVlwZv0hL3vEmEp4FLfia-dMZpxEnEqRxNUen-8IQaRSTpn9fC--ddqE7IfEvSiEEzzXqupP4GisBoj-V4nR2PGGS0m6BY77bsQhA==\" rel=\"nofollow\" target=\"_blank\" title=\"bbegien@oncoc4.com\">bbegien@oncoc4.com<\/a><\/p>\n<p>Alexandra Folias<br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WMwbt5843y0MMRKYYuVE4y2s54Z0pNY8XSGuQmLWYcMpEFb5PP_FyROHK_JzkI--CFnK89oAe-T3VRqr7jCJQ0dj7xkw7nMk24u5lYcKQiQsPmcRb_PhJRBfh405G14m\" rel=\"nofollow\" target=\"_blank\" title=\"afolias@lifesciadvisors.com\">afolias@lifesciadvisors.com<\/a><\/p>\n<p><strong>Media Contact:<\/strong><\/p>\n<p>Jason Braco, Ph.D.<strong>\u00a0<\/strong><br \/>LifeSci Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XmP0mN3p-lHItpKWWNQXITa0BbSDO_2RSlAF9A5xEXez86jDH1LZV4X1I9QkkeWGQXTdl9TRCQaiMk5AQDbOuFLikp01neIzKiIPV0Fi46QdEJKHsrQJYOdfrM7NskXG\" rel=\"nofollow\" target=\"_blank\" title=\"jbraco@lifescicomms.com\">jbraco@lifescicomms.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWE4ODVkMDMtM2ZjMS00NTBkLWIyNTAtODdiZGNlMzhkNDMxLTUwMDA4NjI2Ni0yMDI1LTA0LTE2LWVu\/tiny\/OncoC4-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Oral presentation will feature AI-081, a potentially best-in-class PD-1\/VEGF bispecific antibody and ONC-841, a first-in-class anti-Siglec-10 antibody Initial clinical data for both AI-081 and ONC-841 in solid tumors expected 2H 2025 ROCKVILLE, Md., April 16, 2025 (GLOBE NEWSWIRE) &#8212; OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer today announced that it will [&#8230;]\n","protected":false},"author":1,"featured_media":66730,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-66729","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>OncoC4 Selected to Present at the 2025 AACR Meeting&#039;s Showcase Session - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OncoC4 Selected to Present at the 2025 AACR Meeting&#039;s Showcase Session\" \/>\n<meta property=\"og:description\" content=\"Oral presentation will feature AI-081, a potentially best-in-class PD-1\/VEGF bispecific antibody and ONC-841, a first-in-class anti-Siglec-10 antibody\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-16T12:01:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/04\/OncoC4-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"OncoC4 Selected to Present at the 2025 AACR Meeting&#8217;s Showcase Session\",\"datePublished\":\"2025-04-16T12:01:41+00:00\",\"dateModified\":\"2025-04-16T12:01:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/\"},\"wordCount\":454,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/\",\"name\":\"OncoC4 Selected to Present at the 2025 AACR Meeting's Showcase Session - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2025-04-16T12:01:41+00:00\",\"dateModified\":\"2025-04-16T12:01:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OncoC4 Selected to Present at the 2025 AACR Meeting&#8217;s Showcase Session\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"OncoC4 Selected to Present at the 2025 AACR Meeting's Showcase Session - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/","og_locale":"en_US","og_type":"article","og_title":"OncoC4 Selected to Present at the 2025 AACR Meeting's Showcase Session","og_description":"Oral presentation will feature AI-081, a potentially best-in-class PD-1\/VEGF bispecific antibody and ONC-841, a first-in-class anti-Siglec-10 antibody","og_url":"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2025-04-16T12:01:41+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/04\/OncoC4-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"OncoC4 Selected to Present at the 2025 AACR Meeting&#8217;s Showcase Session","datePublished":"2025-04-16T12:01:41+00:00","dateModified":"2025-04-16T12:01:41+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/"},"wordCount":454,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/","url":"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/","name":"OncoC4 Selected to Present at the 2025 AACR Meeting's Showcase Session - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2025-04-16T12:01:41+00:00","dateModified":"2025-04-16T12:01:41+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/oncoc4-selected-to-present-at-the-2025-aacr-meetings-showcase-session\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"OncoC4 Selected to Present at the 2025 AACR Meeting&#8217;s Showcase Session"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/66729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=66729"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/66729\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/66730"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=66729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=66729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=66729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}